Rhumbline Advisers lowered its stake in Healthpeak Properties, Inc. (NYSE:DOC – Free Report) by 0.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,284,665 shares of the real estate investment trust’s stock after selling 10,655 shares during the quarter. Rhumbline Advisers owned approximately 0.18% of Healthpeak Properties worth $26,040,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also added to or reduced their stakes in DOC. State Street Corp bought a new position in Healthpeak Properties in the 3rd quarter worth about $1,093,576,000. Geode Capital Management LLC bought a new position in Healthpeak Properties in the 3rd quarter worth about $403,898,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Healthpeak Properties in the 3rd quarter valued at about $230,988,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Healthpeak Properties in the 3rd quarter valued at about $175,697,000. Finally, Sumitomo Mitsui Trust Group Inc. purchased a new stake in shares of Healthpeak Properties in the 3rd quarter valued at about $102,615,000. Institutional investors own 93.57% of the company’s stock.
Healthpeak Properties Price Performance
Shares of Healthpeak Properties stock opened at $19.52 on Thursday. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.35 and a quick ratio of 1.35. The business’s 50 day simple moving average is $20.25 and its two-hundred day simple moving average is $21.41. The stock has a market capitalization of $13.65 billion, a P/E ratio of 55.76, a price-to-earnings-growth ratio of 2.15 and a beta of 1.15. Healthpeak Properties, Inc. has a one year low of $16.01 and a one year high of $23.26.
Healthpeak Properties Increases Dividend
Analyst Ratings Changes
Several analysts have weighed in on DOC shares. Wedbush lowered their price target on Healthpeak Properties from $27.00 to $24.00 and set an “outperform” rating on the stock in a report on Friday, February 14th. Mizuho lowered their price target on Healthpeak Properties from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Thursday, December 5th. Wells Fargo & Company lowered their price target on Healthpeak Properties from $23.00 to $22.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 10th. Morgan Stanley raised Healthpeak Properties from an “equal weight” rating to an “overweight” rating and set a $25.00 price target on the stock in a report on Wednesday, January 15th. Finally, StockNews.com cut Healthpeak Properties from a “hold” rating to a “sell” rating in a report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Healthpeak Properties currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.
Check Out Our Latest Analysis on Healthpeak Properties
Healthpeak Properties Profile
Healthpeak Properties, Inc is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates, and develops high-quality real estate for healthcare discovery and delivery.
Featured Stories
- Five stocks we like better than Healthpeak Properties
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- How to Use the MarketBeat Excel Dividend Calculator
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- How Can Investors Benefit From After-Hours Trading
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Healthpeak Properties Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthpeak Properties and related companies with MarketBeat.com's FREE daily email newsletter.